A new manuscript describing the sharing and re-use of data, along with challenges encountered and potential solutions, was just published.

December 2024 PrIMAVeRa is proud to be part of the IMI Antimicrobial Resistance (AMR) Accelerator, an Innovative Medicines Initiative...

A new manuscript focused on data needs for the development of vaccines and monoclonal antibodies (mAbs) to effectively address AMR was...

The third annual meeting of the PrIMAVeRa project took place on 07-08 November 2024 in Seville, Spain. Approximately 35 participants...

The PrIMAVeRa project, a public-private partnership supported by the European Federation of Pharmaceutical Industries and Associations...

Antibiotic resistance is a global public health threat. Modern health systems rely on antibiotics to prevent and treat infections, and...

Activities continue in the PrIMAVeRa project, with the latest result being the publication of a new manuscript titled “Using contact...

Divided into two rounds during June, Consortium partners presented year two progress to SAC.

The team shared challenges & solutions for data-sharing & re-use, and expert consensus on priorities for vaccine/mAb R&D and implementation.

The Cross-Project Meeting gathered nearly 40 participants representing 9 IHI-funded projects from the AMR Accelerator, in Basel, Switzerland

The PrIMAVeRa project proudly announces the simultaneous publication of four informative systematic reviews.

The meeting enabled dynamic panel discussions covering the burden of AMR, and model development and data access.

The PrIMAVeRa project announces the appointment of the Scientific Advisory Committee (SAC).

PrIMAVeRa team gathered for the first project annual meeting with around 30 project partners joining in Verona (IT), and virtually.

The 2-day workshop included an overview of WP2, presentation and discussion of AMR case studies, the draft of AMR protocol, and more.

The PrIMAVeRa consortium held its Kick-off Meeting on 25 November 2021 marking the official launch of this ambitious endeavor.

The IMI2 Joint Undertaking mobilises more than € 9 million to harnessing the power of big data and AI to steer the fight against AMR